- Home
- NUVL vs GTES Comparison
NUVL vs GTES Comparison
Compare NUVL & GTES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GTES
- Stock Information
- Founded
- NUVL 2017
- GTES 1911
- Country
- NUVL United States
- GTES United States
- Employees
- NUVL N/A
- GTES N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GTES Industrial Machinery/Components
- Sector
- NUVL Health Care
- GTES Industrials
- Exchange
- NUVL Nasdaq
- GTES Nasdaq
- Market Cap
- NUVL 5.6B
- GTES 5.2B
- IPO Year
- NUVL 2021
- GTES 2018
- Fundamental
- Price
- NUVL $74.61
- GTES $21.15
- Analyst Decision
- NUVL Strong Buy
- GTES Buy
- Analyst Count
- NUVL 8
- GTES 10
- Target Price
- NUVL $115.50
- GTES $22.70
- AVG Volume (30 Days)
- NUVL 548.5K
- GTES 1.9M
- Earning Date
- NUVL 05-08-2025
- GTES 04-30-2025
- Dividend Yield
- NUVL N/A
- GTES N/A
- EPS Growth
- NUVL N/A
- GTES N/A
- EPS
- NUVL N/A
- GTES 0.83
- Revenue
- NUVL N/A
- GTES $3,393,200,000.00
- Revenue This Year
- NUVL N/A
- GTES $1.40
- Revenue Next Year
- NUVL N/A
- GTES $4.48
- P/E Ratio
- NUVL N/A
- GTES $25.48
- Revenue Growth
- NUVL N/A
- GTES N/A
- 52 Week Low
- NUVL $55.54
- GTES $14.70
- 52 Week High
- NUVL $113.51
- GTES $23.85
- Technical
- Relative Strength Index (RSI)
- NUVL 54.31
- GTES 56.54
- Support Level
- NUVL $70.25
- GTES $20.39
- Resistance Level
- NUVL $75.97
- GTES $21.80
- Average True Range (ATR)
- NUVL 3.09
- GTES 0.47
- MACD
- NUVL 0.13
- GTES -0.13
- Stochastic Oscillator
- NUVL 79.92
- GTES 33.52
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GTES Gates Industrial Corporation plc
Gates Industrial Corp PLC is a manufacturer of engineered power transmission and fluid power solutions. The company has two operating segments; Power Transmission and Fluid Power segments. The Power Transmission solutions convey power and control motion. It is used in applications in which belts, chains, cables, geared transmissions, or direct drives transfer power from an engine or motor to another part or system. The Fluid power solutions are used in applications in which hoses and rigid tubing assemblies either transfer power hydraulically or convey fluids, gases, or granular materials from one location to another. The company generates key revenue from the Power Transmission segment. Company operates in USA, United Kingdom, Luxembourg, EMEA, with majority revenue from USA.